TD Private Client Wealth LLC Has $4.11 Million Stock Position in Merck & Co., Inc. $MRK

TD Private Client Wealth LLC increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 59.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 39,014 shares of the company’s stock after buying an additional 14,533 shares during the period. TD Private Client Wealth LLC’s holdings in Merck & Co., Inc. were worth $4,107,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRK. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the 3rd quarter worth about $31,000. High Note Wealth LLC raised its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares during the last quarter. Tucker Asset Management LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $34,000. Wealth Watch Advisors INC bought a new stake in Merck & Co., Inc. during the 3rd quarter worth about $34,000. Finally, Dunhill Financial LLC raised its holdings in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after purchasing an additional 190 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the subject of several recent research reports. TD Cowen boosted their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Guggenheim upped their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Up 1.1%

NYSE:MRK opened at $112.63 on Tuesday. The company has a market cap of $278.18 billion, a P/E ratio of 31.73, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18. Merck & Co., Inc. has a twelve month low of $75.40 and a twelve month high of $125.14. The business has a 50 day moving average price of $115.94 and a two-hundred day moving average price of $109.54. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.